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Abstract: Cancer research has received a fresh impetus from the 
concept of cancer stem cell (CSC) which postulates the existence of 
a tumor cell population uniquely endowed with self-renewal capacity 
and therapy resistance. Despite recent progresses including targeted 
therapy, lung cancer treatment remains a challenge owing largely to 
disease recurrence. Providing a conceptual model of tumor resistance 
and disease relapse, the lung CSC has received extensive attention, 
leading to a flourishing literature and several ongoing clinical tri-
als. In this study, we will discuss the data suggesting the existence 
of CSC in lung tumors and the potential clinical utility of CSCs as 
prognostic markers or cellular targets of new therapeutic strategies. 
We will also touch on the new fundamental developments of the CSC 
concept that ought to be considered if the integration of the CSC 
concept into clinical practice is to be successful and impact on lung 
cancer treatment.
(J Thorac Oncol. 2014;9: 7–17)
BACKGROUND
Lung cancer is the leading cause of cancer-related death 
in western countries. Available therapeutic options com-
bine surgery, chemo- and radiotherapy, and targeted therapy 
depending on the stage and histological subtype. Even though 
an initial response to these treatments is commonly observed, 
the long-term benefit to patients is compromised by disease 
relapse driven by therapy-resistant tumor cells. Therefore, the 
efficient killing of resistant cells is a major endeavor for out-
come improvement.
Many fields in cancer research have received a fresh 
impetus brought about a decade ago with the cancer stem 
cell (CSC) concept (Fig. 1). Originating from transplantation 
experiments of hematological tumor cells into immunodefi-
cient mice, the CSC concept initially proposed that human 
acute myeloid leukemia comprises functionally unequivalent 
cells organized hierarchically with a leukemia CSC positioned 
at the apex.1 The growth of cancerous tissue thus shows strik-
ing similarities to the corresponding normal hematopoietic 
tissue, and the defining properties of a leukemia CSC, just 
as the normal tissue stem cells, include self-renewal and the 
ability to generate progeny committing to differentiation.
Consequently, the tumor tissue is heterogeneous and 
comprises phenotypically and functionally distinct cell popu-
lations. Sustaining long-term growth in serial transplantation 
assays, the CSCs are considered to be the tumor-initiating 
cells (also sometimes called the tumor-seeding cells). Perhaps 
even more importantly, the CSCs also display resistance to 
drug and are thought to give rise to therapy-resistant tumor 
regrowth after treatment, hence their alternative name of 
tumor-reinitiating cells.
The CSC concept has since been extrapolated to solid 
tumors, and the existence of CSC in lung tumors has recently 
been reported. Properties of the CSCs toward anticancer 
agents have been extensively examined in lung cancer and 
an abundant literature has ensued. Nevertheless, the available 
data ought to be considered cautiously before translation into 
a clinical impact can be reasonably envisaged. In this article, 
we consider the experimental data supporting the relevance 
of the CSC concept to lung cancer, and the arguments for its 
integration into the clinical practice.
STEM AND PROGENITOR CELLS IN THE LUNG
Whether the different cell types of the lung epithelia 
arise from a single multipotent lung stem cell is still a debated 
question even though studies mostly carried out on mouse lung 
rather point to several region-specific, oligopotent progenitors 
ensuring the lung epithelium homeostasis. Several candidate 
cell types have been proposed to fulfill this function.
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A multipotent lung stem cell was first proposed by Kim 
et al.2 This cell expresses both Clara cell and pneumocyte type 
II specific proteins, namely secretoglobin 1a1 (scgb1a1, also 
called CC10 or Clara cell secretory protein [CCSP]) and sur-
factant protein C (SP-C) (prosurfactant apoprotein C), respec-
tively. This candidate lung stem cell can give rise to three 
epithelial cell types, Clara cells and type I and II pneumocytes, 
localizes at the bronchoalveolar duct junction and was hence 
named bronchoalveolar stem cells. By using lineage tracing, 
Rock et al.3 revealed role of the Clara cells in lung airway 
epithelia homeostasis as transit amplifiers derived from basal 
cells and able to self-renew and differentiate into ciliated cells. 
The alveolar epithelium, however, was found to have a distinct 
cellular origin.4 A specific progenitor for the alveolar epithe-
lium has indeed been reported recently.5 In another elegant 
study also using lineage tracing, Chen et al.6 too generated 
data strongly suggesting the existence of several conducting 
airway epithelial progenitors distributed along the proximal-
to-distal axis. More extensive tissue regeneration triggered, 
for example, by experimental lung injury may, however, rely 
on bona fide stem cell activity.7 The few reports suggesting 
the existence of a lung stem cell population able to differenti-
ate into all the different lung epithelial cells are currently still 
awaiting experimental confirmation.8,9
The cellular target of oncogenic transformation in 
the lung has also been the topic of a number of reports. 
Adenocarcinomas, for instance, were first suggested to origi-
nate from the bronchoalveolar stem cells before an alveolar 
origin was recently demonstrated in mouse lung cancer mod-
els.2,10,11 Neuroendocrine cells, and to a lesser extent alveolar 
type II pneumocytes, have been proposed as the cellular origin 
of small-cell lung cancer.12
MARKERS OF LUNG CSCS
Advances in the understanding of normal and CSCs rely 
on specific markers. The combined expression of several lung 
epithelial cell–type markers such as CCSP or SP-C may enable 
the characterization of putative tissue stem cells, but has not 
been reported to identify lung CSCs so far. The transmem-
brane glycoprotein prominin 1, also known as CD133, has no 
known function but was identified as a hematopoietic stem cell 
marker.13 Its expression has since been reported in other tissues 
and CSCs. After CD133 was shown to label a population of 
lung tumor cells endowed with CSC properties,14 many reports 
have followed suit and used CD133 as a CSC marker.15–19
ALDH1 is a member of the detoxifying aldehyde dehy-
drogenase family. High expression of ALDH1 is observed in 
tissue stem cell (SC) as well as CSC in lung tumors.20–25 The 
stromal cell–derived factor-1 (SDF-1, also known as CXCL12) 
membrane receptor CXCR4 is an another commonly used 
marker for lung CSC.26,27 A number of other membrane mark-
ers, previously demonstrated to label CSC in other cancers, have 
been used to identify lung CSC, as for example CD44, CD166, 
interleukin-6R, or urokinase-type plasminigen activator recep-
tor (uPAR).28–31 Interestingly, stem cell–related pathways such 
as Notch activity have been associated with lung CSCs.25,32
When assessed across 10 human non–small-cell lung 
cancer (NSCLC) cell lines, the expression of the afore-men-
tioned markers varied greatly among cell lines and did not 
correlate to each other.28 Besides, CXRC4-sorted lung CSC 
did not consistently coexpress other previously reported CSC 
markers.27 Therefore, there is no reliable single lung CSC 
marker reported as yet. Nevertheless, other well-established 
strategies such as the exclusion of the DNA-binding dye 
Hoechst 33342 can be used to identify and isolate stem cells. 
A Hoechst-negative lung CSC population, also called side 
population, has been identified and isolated by flow cytometry 
from lung cancer cell lines and tumor samples.33,34 However, 
the side population isolated either from lung cancer–derived 
cell lines or from resected tumor samples did not coexpress 
the previously described CSC markers.27,34 The preclinical 
data generated based on these CSC markers, while prompting 
FIGURE 1.  Timeline of the key discoveries to the concept of CSC in lung cancer. CSC, cancer stem cell.
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cautious interpretation, have nonetheless contributed to the 
current understanding of therapeutics resistance.
PROPERTIES OF LUNG CSC TOWARD 
ANTICANCER TREATMENTS
Resistance to Chemotherapy
Cytotoxic chemotherapy is the main first-line treatment for 
advanced/metastatic lung cancers, often achieve an initial thera-
peutic response but provides limited long-term benefit to patient 
because of the recurrence of the disease. The topic of resistance 
of lung CSCs to chemotherapy is therefore an outstanding issue 
for the improvement of lung cancer treatment. The experimental 
exploration of CSC properties toward chemotherapy has relied 
on three main experimental strategies (Fig. 2 and Table 1).
Fluorescence-Activated Cell Sorting/Magnetic Beads 
Sorting of Lung CSC
This experimental approach consists in sorting a cell 
population based on the expression of the previously dis-
cussed CSC markers. In most reports, the stemness of the 
sorted population is confirmed in vitro, for example, by the 
sphere-formation assay described below or by using the stan-
dard procedure subcutaneous transplantation assay as an in 
vivo read out of tumorigenicity. The sensitivity of the sorted 
cells to chemotherapeutic agents can then be evaluated and 
compared with the bulk, parental population or to the non–
stem-cell population in in vitro assays (Fig. 2).
By using this approach, we have shown that lung cancer 
cell line–derived CD133-positive subpopulations were able to 
form spheres and displayed increased resistance to cisplatin 
and other chemotherapeutic agents.14,35
To model human cancer more faithfully, xenograft 
models of human tumors have been established in which the 
tumorigenic potential of the CD133-expressing lung CSCs 
was examined.16 Of note, no correlation was found between 
the expression of CD133 in the original tumor and the ability 
to form a xenograft, suggesting that histological assessment of 
CD133 expression may not directly relate to the tumor-seeding 
potential. Nevertheless, combining in vitro and in vivo assays, 
CSC properties of the CD133-expressing population could 
indeed be demonstrated. Furthermore, in cisplatin-treated 
xenografts, CD133-positive tumor cells were enriched in a 
fraction of the samples. However, sorting CD133-expressing 
CSCs derived from human lung cancer cell lines, Meng et al.36 
did not observe resistance of the putative CSC population to 
chemotherapy when assessed by in vivo tumorigenicity assays.
The two alternative markers CXCR4 and CD44 have 
also been shown to label cisplatin-resistant lung CSC.27,28 In 
line with the reports suggesting an increased resistance of lung 
CSC to chemotherapy, the side population of a panel of human 
lung cancer cell lines was also shown to be resistant to the 
chemotherapeutic agents cisplatin, etoposide, gemcitabine, 
daunorubicin, doxorubicin, vinorelbine, and docetaxel in in 
vitro cell-proliferation assays.34
Sphere-Forming Cell Population
Another commonly used approach to study CSCs relies 
on their unique ability to grow in suspension as spheres, 
sometimes also called spheroids or spheroid bodies. This is 
usually achieved when cells are cultured in specific conditions 
including low adherence substrate and the tightly controlled 
growth factor composition of culture media.37,38 As mentioned 
previously, this assay can not only be used to confirm stemness 
of a prospectively isolated population but can also be a mean to 
enrich a population of CSC cells in vitro (Fig. 2). One obvious 
advantage of this approach is that CSC markers are not required.
Cancer cell line–derived or primary tumor-derived sphere-
forming cells were shown to be more tumorigenic than the cor-
responding bulk population in transplantation experiments and 
are also more resistant to cisplatin and irradiation. Two reports 
have identified a specific DNA damage response (DDR) of the 
sphere-forming cells as the mechanistic basis of resistance to 
DNA damage-generating treatment, even though a context-spe-
cific regulation of the DDR machinery was observed.39,40
Exploring the pathways required for the maintenance 
of chemotherapy-resistant lung CSCs, Levina et al.41 identi-
fied the stem cell factor-c-kit axis activity as a major determi-
nant of stemness and therapy resistance in NSCLC cell lines. 
Disrupting this signaling pathway prevents both the formation 
of CSC sphere and the emergence of resistant clones when 
tested in vitro.
Selection of Therapy-Resistant Cell Population
Finally, a third common approach to study the ability of 
stem cells to resist therapeutic agents relies on the selection of 
a resistant population (Fig. 2).
A number of articles report on the in vitro selection 
of a population of lung cancer–derived cell lines based on 
their ability to survive chemotherapeutic treatments such as 
5-fluorouracil and methotrexate,30 cisplatin,18,42,43 doxorubi-
cin, or etoposide42 (Table 1). Several in vitro assays were per-
formed to assess whether the drug-resistant cells did display 
CSC properties, such as the expression of membrane (CD133, 
CD44, interleukin-6R) and functional (ALDH, ABCG2) 
markers. Stem cell–associated transcriptional programs were 
also expressed in resistant cells. This selected population also 
formed spheres in vitro and tumors in transplantation assays, 
providing functional evidence of their CSC activity. One 
study, however, reports no enrichment of stem cells after drug 
selection raising questions about the reproducibility of this 
experimental strategy.18
To address the resistance of lung CSC to therapeutic 
agents in vivo, Bertolini et al.16 analyzed expression of CSC 
markers in residual human tumor xenograft after cisplatin 
treatment. The residual, resistant tumor cells were enriched 
for CD133 expression in a subset of the samples tested. 
However in a conflicting study, Hegde et al.44 used xeno-
graft and a genetically modified mouse model of lung cancer 
relapse after chemotherapy. Upon treatment, no consistent 
enrichment in expression of CSC markers was observed in the 
residual disease. Instead, the proportion of CD133-, CD44-, or 
CD117-expressing cells varied across the models. The tumor-
reinitiating capacity of the residual, chemotherapy-resistant 
cancer cells and the expression of the CSC markers were not 
correlated when tested in subcutaneous or orthotopic trans-
plantation experiments. Showing that the cells responsible for 
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Non CSC
FIGURE 2.  Experimental strategies to the study of lung CSC resistance to anticancer therapy. The lung CSC can either be isolated 
from lung cancer–derived cell lines, from primary patient tumors, or from xenografted or GEMM tumors. The CSC population can be 
isolated by FACS- or magnetic beads–based technologies using cell membrane or functional markers of CSCs. The CSC identity of the 
putatively sorted population is then assessed in vitro by gene expression analysis, clonogenicity, or sphere-formation assay. In vivo, the 
CSC identity is generally assessed by subcutaneous xenotransplantation. The effect of chemotherapeutic agents on the CSC population 
can then be examined and compared with the non-CSC population. Alternatively, a therapeutic-resistant population can be isolated 
and the CSC traits of this population assessed in vitro or in vivo as previously mentioned. Finally, a population of CSCs can be isolated 
based on their specific ability to grow on low adherence substratum and form spheroid bodies. CSC, cancer stem cell; GEMM, geneti-
cally engineered mouse model; FACS, fluorescence-activated cell sorting. 
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TABLE 1.  Reports on the Resistance of Lung CSCs to Chemo- and Targeted Therapy
Models
Isolation 
of the CSC 
Subpopulation
Functional 
Analysis of 
Stemness
Validation in 
Tumor Samples
Testing of CSC 
Drug Resistance
Reference ConclusionIn Vitro In Vivo In Vitro In Vivo
Chemotherapy
  Lung cancer 
cell lines
Selection of 
therapy- 
resistant cells
Yes Yes Levina et al., 2008 Drug-resistant cells have 
CSC properties
Cui et al., 2011 No enrichment of CD133+ 
after drug selection. 
Drug-resistant cells have 
no CSC properties
Yi et al., 2012 Drug-resistant cells 
express CSC markers
Barr et al., 2013 Drug-resistant cells express 
CD133, CD44, ALDH
  Lung cancer 
cell lines
FACS sorting Yes Yes FACS (SP in 
resected tumor 
samples) or 
IHC
Yes Ho et al., 2007 SP is more resistant to 
chemotherapy and more 
tumorigenic
Meng et al., 2009 CD133 does not label 
tumor-forming and drug-
resistant lung CSCs
Leung et al., 2010 Only CD44+ cells form 
spheres and tumors
CD44-expressing cells 
resist to Cisplatin
Nian et al., 2011 CXCR4-positive cells 
are more tumorigenic 
and more resistant to 
cisplatin
  Dissociated 
patient tumor 
cells
FACS sorting Yes Yes Yes Eramo et al., 2008 Lung CSCs are more 
resistant to therapy
  Lung cancer 
cell lines
Selection of cells 
able to form 
spheres
Yes Levina et al., 2010 CSCs rely on SCF-cKit. 
CSCs resist to cisplatin. 
Combination of cisplatin 
plus c-kit inhibitor have 
greater efficiency
  Lung cancer 
cell lines
Selection of cells 
able to form 
spheres
Yes  Yes Yes Lundholm et al., 
2013
Sphere-forming cells are 
resistant to cisplatin and 
IR due to a reduced DDR
  Lung cancer 
cell lines
FACS sorting + 
CD133 promoter- 
driven expression 
of GFP
Yes IHC Yes Yes Liu et al., 2012 CD133-expressing cells are 
resistant to anticancer 
therapy. Inhibition of 
the Notch pathway 
prevents emergence of 
CD133+ resistant cells
  Lung cancer 
cell lines and 
dissociated 
GEMM tumor 
cells
In vivo selection of 
drug- 
resistant cells
Yes Yes Hedge et al., 2012 No enrichment in stem cell 
markers in TRICs. No 
increased tumorigenicity
  FFPE + 
dissociated 
tumor
Yes IHC Yes Salnikov et al., 
2010
Correlation between 
expression of CD133 
and resistance genes in 
tumor.
No prognostic value
  Dissociated 
patient tumor 
cells
Selection of cells 
able to form 
spheres
Yes Yes Yes Bartucci et al., 
2012
CHK1 inhibition 
potentiate 
chemotherapy by 
sensitizing NSCLC 
CSCs
(Continued )
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relapse do not have all CSC features, this report suggests that 
tumor-initiating capacities and tumor regrowth after treatment 
may rely on distinct cell population or be a dynamic trait.
Resistance to Targeted Therapy
Endothelial Growth Factor Receptor
Similar to chemotherapy, the therapeutic efficacy of 
targeted agents such as endothelial growth factor receptor 
(EGFR) inhibitors is hampered by the emergence of resis-
tance. Well-described, genetically driven mechanisms of 
resistance to EGFR tyrosine kinase inhibitor (TKI) involve 
either desensitizing mutations within the EGFR receptor 
itself or genetic alteration of other genes along the pathway. 
Nevertheless, these alterations explain only a fraction of the 
resistance observed in the clinic and other mechanisms based 
on the activity of lung CSCs have been proposed.
By selecting an EGFR-TKI–resistant lung cell line 
population, CSC traits were shown to be acquired by the 
resistant cells.45 The CXCR4/SDF-1α axis was shown to be 
involved in the generation of stem cell–like resistant cells.26 
In another report, an insulin-like growth factor-1–mediated 
transient chromatin modification was the basis of a sponta-
neously arising phenotypic heterogeneity within the popula-
tion that allowed the generation of resistant cells.46 Of note, 
the drug-tolerant cells were enriched in the stem cell markers 
CD133 and CD24. The enrichment was then lost as these per-
sistent cells started to proliferate again, confirming the tran-
sient nature of the epigenetically induced CSC phenotype and 
the dynamic nature of heterogeneity.
Resistance to Ionizing Radiation
Normal tissue and CSCs are uniquely equipped to sur-
vive genotoxic stresses such as ionizing radiation.47,48 The 
rationale to examine the response to radiation in lung CSC 
is obvious as resistance to radiotherapy is often observed in 
the clinic. Several of the previously mentioned reports assess-
ing the resistance of CSC to chemo- and targeted therapy 
have also examined the resistance of lung CSC to radiation. 
Lundholm et al.,39 for example, studied sphere-forming CSC-
like cells and found that when compared with their more 
differentiated counterpart, these cells display an increased 
radioresistance. Jung et al.26 also assessed the radiosentitiv-
ity of CXCR4-positive, gefitinib-resistant cells and observed 
a moderate resistance to ionizing radiation. In an interesting 
preclinical study, the targeting of ALDH-positive CSCs by the 
telomerase inhibitor MTS312 combined to radiation resulted 
in a cumulative effect in vitro, suggesting that the radiation-
resistant population is an ALDH-positive CSC population.24 
Finally, focusing specifically on the CSC resistance to ioniz-
ing radiation, Mihatsch et al.49 selected in vitro a radioresistant 
  Dissociated 
patient 
tumor cells 
xenografts
FACS + magnetic 
beads sorting of 
CD133 marker(s) 
expression 
and functional 
properties
Yes Yes Yes Bertolini et al., 
2009
CD133 marks tumor- 
initiating cells. Cisplatin-
resistant cell lines, but 
not tumor xenograft, are 
enriched in CXCR4 and 
ABCG2 expression but 
not CD133
EGFR inhibitors
  Lung cancer 
cell lines
Selection of 
therapy- 
resistant cells
Yes Sharma et al., 
2010
Drug tolerance in CSCs is 
mediated by IGFR-1R 
and chromatin state
Ghosh et al., 2012 Resistant cells are enriched 
for CD133, SSEA-
3, SSEA4, Tra1-81 
expression and Hoechst 
exclusion capacity
  Lung cancer 
cell lines
Selection of 
therapy- 
resistant cells
Yes Yes Jung et al., 2013 Resistant cells are 
dependent on CXCR4 
signalling and have 
increased sphere- 
forming capacities
The table shows the various models used to investigate lung CSC response to therapy, the mean for CSC identification, and isolation as well as the functional analysis of stem 
cell properties of the isolated population. In vitro functional assessment of stemness can comprise colony formation, migration, self-renewal and sphere-formation assays, or gene 
expression analysis. For in vivo functional assays, tumor-formation assay in subcutaneous transplant experiments is most commonly performed. Some reports also include a validation 
of the CSC marker(s) used in patient tumor samples. The sensitivity of CSCs to chemotherapeutics can be measured in vitro or in vivo. The conclusions of the reports are in bold when 
confirming or in italics when contradicting, a role of lung CSC in resistance to anticancer treatments.
CSC, cancer stem cell; GEMM, genetically modified mouse model; EGFR, endothelial growth factor receptor; IHC, immunohistochemistry; DDR, DNA damage response; TRICs, 
tumor reinitiating cell; NSCLC, non–small-cell lung cancer; IGFR-1R, insulin-like growth factor 1 receptor; SSEA-3, stage specific embryonic antigen-3; FFPE, formalin-fixed 
paraffin-embedded; FACS, fluorescence-activated cell sorting; GFP, green fluorescent protein; SP, side population; IR, ionizing radiation.
TABLE 1. (Continued )
Models
Isolation 
of the CSC 
Subpopulation
Functional 
Analysis of 
Stemness
Validation in 
Tumor Samples
Testing of CSC 
Drug Resistance
Reference ConclusionIn Vitro In Vivo In Vitro In Vivo
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lung cancer cell line subpopulation. When compared with the 
parental cell line, the radioselected cells neither displayed 
a stem cell–related gene expression program nor were they 
enriched for CD133 expression. However, an increased activ-
ity of ALDH1 could be observed in the resistant cells.
PROGNOSTIC AND PREDICTIVE SIGNIFICANCE 
OF CSC IN LUNG CANCER
The presence of CSC has been correlated with poor 
survival in a number of solid tumors including glioblastoma, 
colon cancer, or pancreatic cancer.50–52 An increase in CD133 
level was also reported in cisplatin-relapsed NSCLC.35 Even 
though CD133 expression is correlated to the expression of 
genes involved in the repair of chemotherapy-induced DNA 
damage such as thymidylate synthase and O6-methylguanine-
DNA methyltransferase, its expression was not correlated 
to survival.53 A series of other reports also concluded by the 
absence of prognostic value for CD133 expression.19,25,54
The prognostic value of CD44 in NSCLC was also 
examined and led to conflicting results.28,55 On the contrary, 
reports converge toward a prognostic role of the CSC quan-
tification when based on functional CSC markers. ALDH 
activity in NSCLC correlates with poor survival.21,25 The ATP-
binding cassette-transporter breast cancer resistance protein 1 
(BRCP1) was also associated with poor prognosis and a poor 
response to cisplatin-based chemotherapy, pointing to a poten-
tial predictive value of BRCP1 expression that was however 
not confirmed in early-stage NSCLC.54,56,57
In an interesting study, NSCLC CSCs were sorted based 
on the expression of the CSC membrane marker CD166.29 
Transcriptomic analysis of the tumor-initiating CSCs identi-
fied glycine decarboxylase (GLDC) as an enzyme specifically 
expressed in tumor-initiating CSC. Importantly, GLDC-expressing 
CSCs represented only a subset of the CD166-positive cells, 
and although CD166 did not have a prognostic significance in 
NSCLC, high expression of GLDC correlated with poor survival. 
This study corroborates the potential superiority of functional 
markers in identifying clinically relevant lung CSC populations.
Finally, another mean to assess the abundance of CSC 
within tumors could be the search for embryonic stem cell expres-
sion signature, as Hassan et al.58 suggested a correlation between 
embryonic stem cell expression program and markers of poor 
prognosis and worse overall survival in lung adenocarcinomas.
CSC, A POTENTIAL CONTRIBUTOR TO 
IMPROVEMENT OF LUNG CANCER 
TREATMENT?
Targeted Eradication of CSC
Several preclinical studies have identified pathways 
involved in the stemness maintenance of CSC that can poten-
tially be pharmacologically disrupted and lead to CSC deple-
tion by enforcing their differentiation (Fig. 3). The Notch 
pathway, for instance, is required for the regulation of self-
renewal in many biological systems and its inhibition by a 
γ-secretase inhibitor leads to the specific elimination of CSC 
in a preclinical study.25 The efficacy of a γ-secretase inhibitor, 
RO4929097, as a single agent in NSCLC is currently being 
evaluated clinically (NCT01193868).
The Wnt pathway is another key regulator of self-
renewal. The disruption of its activity using a monoclonal 
antibody antagonist of Wnt-1 and -2 has shown promising 
antitumor effects in lung cancer, even though these effects 
were not shown to be underpinned by CSCs.59 Inhibitors of 
the canonical Wnt pathway β-catenin transcriptional activity 
have also been developed and one of them has entered phase I 
clinical trial (NCT01302405).
Finally, the Hedgehog pathway is another important 
contributor to the regulation of stemness. There are some pre-
clinical indication that interfering with hedgehog signaling 
can have antitumor effects in the lung through alteration of 
the CSC function.60 Clinical studies have yet to be undertaken 
to investigate the effect of Hedgehog pathway inhibition as a 
single agent in lung cancer. However, there are currently four 
clinical trials evaluating the inhibition of the Hedgehog path-
way in combination with chemotherapy.
Combination Therapy
Hedgehog Pathway
As hedgehog pathway disruption hits CSC in the lung,60 
and that the CSC population has been shown to resist che-
motherapy, there is a clear rational to combine both therapies 
in order to increase treatment efficacy (Fig. 3). Four clinical 
trials are currently evaluating the combination of Hedgehog 
pathway inhibitors to chemotherapy (NCT00887159, 
NCT01579929, NCT01722292, NCT00927875).
Notch Pathway
In a preclinical study, inhibiting the Notch pathway 
could prevent the emergence of CD133-positive, therapy-
resistant lung CSC.35 Whether these findings could be con-
firmed in a clinical setting is currently under investigation in 
several clinical trials, one of them testing the combination 
of Notch pathway disruption using monoclonal antibody to 
Notch ligand DLL4 (delta like 4) and cytotoxic chemotherapy 
(NCT01189968). In another clinical study, the targeted thera-
peutic agent Erlotinib is combined to a γ-secretase inhibitor 
(NCT01193881). Whether this combination prevents the sys-
tematically observed emergence of EGFR-TKI–resistant can-
cer cells is of outstanding clinical and basic interest.
CXCR4 Signaling
Like Notch inhibition, disruption of the SDF1-CXCR4 
can interfere with lung CSC maintenance. Thus inhibition of 
STAT3, an effector of the CXCR4 signaling pathway, in this 
context by WP1066 or siSTAT3 can prevent the emergence of 
gefitinib-resistant NSCLC cell.26 The relevance of these find-
ings remains to be evaluated clinically.
c-kit Signaling
Finally, in a preclinical study, c-kit signaling was 
found to be involved in maintenance of lung CSC.41 In these 
experimental conditions, the inhibition of the SCF-c-kit axis 
by imatinib interfered with CSC self-renewal and lead to a 
better response to cisplatin. There is therefore also a strong 
rational of combining chemotherapy to c-kit pharmacological 
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inhibition which is currently being tested in a phase II clinical 
trial (NCT00156286).
Targeting Resistance Pathways
Preventing Drug Efflux
The expression of efflux transporters is a hallmark of 
stem cells and is exploited experimentally to isolate the side 
population. There are a number of conflicting reports on the 
role of the efflux transporters in the resistance of tumor cells 
to chemotherapy. Decreased uptake of drugs is commonly 
reported, and changes in transporters expression often cor-
relates to resistance.61 When tested in genetically modified 
mouse model of lung cancers, however, this mechanism did 
not play a major role in resistance and whether interfering 
with transport can increase chemotherapy efficacy could not 
be confirmed in clinical trial as yet (NCT00042315).62
Modulating the DDR to Avoid Resistance to DNA Damage
Among the mechanisms that have been proposed 
for the increased resistance of CSC to radiotherapy and 
DNA-damaging chemotherapeutic agents, the increased abil-
ity to repair DNA damage stands as a good candidate. The 
PI3K/Akt signaling is an important regulator of the DNA 
double-strand break repair pathways, particularly the nonho-
mologous end joining pathway, through its DNA-dependent 
protein kinase (DNA-PK) regulatory activity.63 On the basis 
of the observation that a CSC-like radioresistant population 
also displayed an increased DNA double-strand break repair 
capacity, Mihatsch et al.49 found that inhibition of PI3K could 
sensitize this resistant population to ionizing radiation. These 
results provide a mechanistic rational to future clinical trials.
Finally, the checkpoint protein CHK1 was identified as 
a mediator of the DNA damage checkpoint specifically acti-
vated in drug-resistant lung CSCs.40 As a result, the combina-
tion of a CHK1 inhibitor with the chemotherapeutic agents 
cisplatin and gemcitabine seems effective at preventing tumor 
growth in vivo. A phase II clinical trial testing the combina-
tion of the CHK1 inhibitor LY2603618 to chemotherapy is 
currently testing these preclinical findings (NCT01139775).
A B C D
FIGURE 3.  Challenges to clinical integration of lung CSC. A, A model integrating the different sources of tumor heterogene-
ity is presented and includes the genetically based clonal evolution (vertical doted arrow, clones are shown with different nuclei 
colors) and the nongenetic mechanisms of phenotypic heterogeneity (horizontal dotted arrow, the CSCs are represented as 
rounded cells). B, Chemotherapy primarily hits actively dividing cells and may therefore spare quiescent lung CSCs, subse-
quently leading to tumor relapse. C, Several pharmacological modulators of the Hedgehog, Notch, and Wnt signaling pathways 
can potentially deplete the lung CSC pool by enforcing their differentiation. According to recent observations, however, CSC 
may arise from the dedifferentiation of differentiated cells, potentially compromising the efficacy of differentiation therapies. 
D, Several mechanisms may contribute to the relapse ensuing targeted therapy such as the EGFR-TKI inhibition. First, genetic 
heterogeneity may generate resistant clones. Second, quiescent lung CSCs can resist therapy by alternative mechanisms and 
lead to disease relapse. From this model, tumor eradication may only be achieved by a combination therapy effecting differenti-
ated and stem-like lung tumor cells. Combination therapies currently being evaluated in clinical trials are materialized by double 
arrows on the right-hand side. CSC, cancer stem cell; EGFR, endothelial growth factor receptor; TKI, tyrosine kinase inhibitor.
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Modulating Epigenetics
Transient epigenetic modulation is the basis of a recently 
identified mechanism of resistance of a lung cancer cell line 
to EGFR-TKI.46 Interfering with the corresponding epigenetic 
machinery or with the upstream signaling that involves insu-
lin-like growth factor-1 can prevent the emergence of resistant 
cells. Whether this mechanism also takes place in vivo and 
can have a therapeutic effect remains to be explored.
Targeting Telomerase Activity
Finally, NSCLC cell line–derived CSCs that display high 
ALDH activity also have longer telomeres and as a result were 
preferentially targeted by the telomerase inhibitor MTS312 in 
vitro and in xenograft models.24 To our knowledge, no clinical 
trial has confirmed these findings yet.
CONCLUDING REMARKS
The role of lung CSCs in tumor development and dis-
ease relapse has still to be firmly demonstrated. On the basis 
of an incomplete basic understanding of the lung CSC biology, 
conflicting results have been generated on candidate markers 
as well as on their potential clinical impact, be it as a mean to 
improve prognosis, or as a cellular target for novel therapeu-
tics. Of note, the architectural complexity of the lung and the 
possible existence of multiple region-specific tissue stem cells 
may make the characterization of lung CSC markers a particu-
larly challenging endeavor.
One of the main impediments to the exploration of lung 
CSC properties probably lies in the experimental approaches 
most often combining cell lines and in vitro assays. First, the 
use of cell lines does not recapitulate the various sources of 
tumor heterogeneity. Indeed, many tumors are now widely 
recognized to be composed of multiple cancer cell clones 
(genetic-based heterogeneity), within which a phenotypical, 
non–genetic-based heterogeneity brings an additional level of 
complexity.46,64–66 Second, CSC markers and functional tests 
such as the sphere-forming assays have been validated in 
other systems and are assumed to be applicable to lung CSC. 
Perhaps, the use of primary tumor material in experimental 
FIGURE 4.  Future research strategies for the evaluation of the clinical potential of lung CSCs. The flowchart highlights the key 
steps for the demonstration of the lung CSC existence and its potential clinical significance. Examples of possible experimental 
approaches are listed. CSC, cancer stem cell.
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settings modeling more closely the natural tumor microen-
vironment—such as the orthotopic xenograft or the embry-
onic lung organoid assay—is mandatory to gain the basic 
insight into the identity and property of lung CSC that could 
enable the validation of more convenient experimental models 
(Fig. 4). Indeed, in the absence of the tumor microenviron-
ment, the behavior of the CSC in these experimental settings 
may have limited relevance to the clinical setting, especially 
regarding their ability to sustain tumor growth and to resist 
therapeutic agents. Finally, among the most recent fundamen-
tal developments in the field of CSC research, recent reports 
point toward the dynamic nature of the CSCs phenotype, 
enabling differentiated cells to acquire CSC phenotype.67,68 
This property of CSC should be considered for experimental 
strategy as well as therapeutic design.
In conclusion, the CSC hypothesis has generated 
much excitement in the field of lung cancer basic and clini-
cal research. The concept bears unquestionable interest to 
understand the mechanisms of tumorigenesis and resistance 
to therapy. It is probably still early times to predict how the 
basic knowledge generated will impact clinical practice, but 
considering the recent advances in the field, we believe that 
a positive impact on lung cancer treatment can be reasonably 
hoped for.
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